开发叶酸结合的miR-34a治疗前列腺癌治疗药物:挑战和前景
bioRxiv : the preprint server for biology
|December 4, 2023
概括
通过叶酸结合的微RNA-34a (miR-34a) 的向输送显示出前列腺癌 (PCa) 治疗的前景. 然而,PCa细胞中受体的有限表达对有效的叶酸-miR-34a疗法提出了挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物运输 药物运输 药物运输
背景情况:
- 前列腺癌 (PCa) 是男性癌症死亡的主要原因,通常是由异质癌症干细胞 (PCSCs) 驱动的,这些干细胞赋予治疗耐药性.
- 微RNA-34a (miR-34a) 通过向关键生存分子,表现出抗PCSC活性,但其治疗应用受到传递挑战和毒性的阻碍.
- 叶酸结合的miR-34a (叶酸-miR-34a) 通过向叶酸受体α (FOLR1) 在其他癌症中显示出有效性.
结论:
- 由于目标受体 (如FOLR1.1) 的表达不够,因此,将叶酸-miR-34a 具体输送到PCa是具有挑战性的.
- 这项研究强调了在前列腺癌治疗中需要替代性策略来治疗连接体结合的miR-34a疗法.
- 研究结果提供了关于联结核酸治疗PCa的局限性和潜力的见解.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K